左乙拉西坦治疗2岁以下婴幼儿癫痫有效性及安全性研究

doi:10.11852/zgetbjzz2017-25-10-18

中国儿童保健杂志 ›› 2017, Vol. 25 ›› Issue (10): 1041-1044.DOI: 10.11852/zgetbjzz2017-25-10-18

左乙拉西坦治疗2岁以下婴幼儿癫痫有效性及安全性研究

叶高波¹,董建鹏²,李丹¹,刘宇¹,王雪莹¹,杨琳¹,黄绍平¹

1 西安交通大学第二附属医院儿科,陕西西安 710004;
2 西安市北方医院儿科,陕西西安 710043

收稿日期:2017-04-26 发布日期:2017-10-10 出版日期:2017-10-10
作者简介:叶高波(1984-),男,住院医师,硕士研究生,主要研究方向为儿童神经系统疾病方向研究。
基金资助:
国家自然科学基金-面上项目(30973224)

Study on the effectiveness and safety of Levetiracetam in the treatment of epilepsy in infants under 2 years old

YE Gao-bo¹,DONG Jian-peng²,LI Dan¹,LIU Yu¹,WANG Xue-ying¹,YANG Lin¹,HUANG Shao-ping¹

1 Department of Pediatrics,the Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shaanxi 710004,China;
2 Department of Pediatrics,Xi'an North Hospital,Xi'an,Shaanxi 710043,China

Received:2017-04-26 Online:2017-10-10 Published:2017-10-10
Contact: YANG Lin,E-mail:yr_1217@163.com

摘要/Abstract

摘要： 目的评估2岁以下癫痫婴幼儿应用左乙拉西坦(LEV)的疗效及安全性,为临床有效防治提供参考依据。方法对2010年1月-2011年12月西安交通大学第二附属医院儿科神经专科住院确诊的2岁以下癫痫患儿中,服用LEV的39例患儿进行临床分析,收集患儿发作类型、家族史、影像学等资料,并进行为期6~72个月的随访,评估患儿治疗情况、疗效及不良反应等。结果左乙拉西坦单药治疗终量有82.7%的患儿为中低剂量,添加治疗剂量组70%的患儿为高剂量。左乙拉西坦治疗2 岁以下癫痫患儿,6个月总有效率为82.1%,完全控制率为61.5%。其中,对于局灶性发作、强直阵挛发作有效率分别为76%和55.6%,对于失张力及肌阵挛发作效果差。单药及添加治疗的不良反应发生率均较低,提示左乙拉西坦具有较高安全性。结论左乙拉西坦是一种广谱有效的抗癫痫药物,作为单药治疗或添加治疗对部分或全面性发作均具有良好疗效,具有较高的耐受性及保留率,是2岁内儿童癫痫一种有益的选择。

关键词: 癫痫, 左乙拉西坦, 婴幼儿

Abstract: Objective To evaluate the efficacy and safety of levetiracetam used in the infants of epilepsy under 2 years old. Methods A total of 39 patients who were diagnosed with epilepsy,under the age of 2,taken the levetiracetam,hospitalized in pediatric neurological from January 2010 to December 2011 were retrospectively evaluated.Seizure type,family history and imaging were collected.Patients were followed up for 6~72 months to evaluate the treatment condition,efficacy and adverse reactions. Results The treatment dosage in monotherapy group was mainly given as a lower dosage (82.7%),while that in add-on therapy group was mainly in high doses (70%).After 6 months' follow-up,the total effective rate was 82.1%,and the total control rate was 61.5%.Among them,the efficacy rates in focal seizure and the tonic-clonic seizure were 76% and 55.6%.The levetiracetam may be useless on the atonic seizure and myoclonic seizure.Also,the adverse reactions rarely occurred,suggesting that the levetiacetam was safe. Conclusion Levetiracetam is a broad-spectrum antiepileptic drug and has high tolerance and retention rate.It is promising to be a helpful choice for the epilepsy children within 2 years old.

Key words: epilepsy, Levetriacetam, infant

中图分类号:

R179

叶高波,董建鹏,李丹,刘宇,王雪莹,杨琳,黄绍平. 左乙拉西坦治疗2岁以下婴幼儿癫痫有效性及安全性研究[J]. 中国儿童保健杂志, 2017, 25(10): 1041-1044.

YE Gao-bo,DONG Jian-peng,LI Dan,LIU Yu,WANG Xue-ying,YANG Lin,HUANG Shao-ping. Study on the effectiveness and safety of Levetiracetam in the treatment of epilepsy in infants under 2 years old[J]. journal1, 2017, 25(10): 1041-1044.

参考文献

[1] 沈晓明,王卫平.儿科学[M].北京:人民卫生出版社,2008:182-184.
[2] Kanemura H,Sano F,Tando T,et al.Efficacy and safety of add-onlevetiracetam in refractory childhood epilepsy[J].Brain and Development,2013,35(5):386-391.
[3] Robert S,Carlos A,Alexis A,et al.A practical clinical definition of epilepsy[J].Epilepsia,2014,1:1-8.
[4] Kwan P,Brodie MJ.Early identification of refractory epilepsy[J].N Engl J Med,2000,342(5):314-319.
[5] Brodie MJ,Barry SJ,Bamagous GA,et al.Patterns of treatment response in newly diagnosed epilepsy[J].Neurology,2012,78(20):1548-1554.
[6] 刘腾.左乙拉西坦的药理和临床评价[J].中国新药杂志,2007,16(9):733-735.
[7] Mohamad Z,Koubeissi MD.Monotherapy in newly diagnosed epi-lepsy:Levetiracetam versus standard anticonvulsants[J].Epilepsy Currents,2014,14(5):255-256.
[8] Pina-Garzn JE,Schiemann-Delgado J,Yang H,et al.Adjunctive levertiracetam in patients aged 1 month to <4 years with partial onset seizures:subpopulation analysis of a prospective,open label extension study of up to 48 weeks[J].Clin Ther,2010,32(11):1935-1950.
[9] Li J,Xiao N,Chen S.Efficacy and tolerability of levetiracetam in children with epilepsy[J].Brain & Development,2011,33(2):145-151.
[10] Pina-Garzn JE,Schiemann-Delgado J,Yang H,et al.Adjunctive levertiracetam in patients aged 1 month to <4 years with partial onset seizures:subpopulation analysis of a prospective,open label extension study of up to 48 weeks[J].Clin Ther,2010,32(11):1935-1950.
[11] 李立敏,王宁,胡海鹏,等.左乙拉西坦治疗儿童癫痫疗效观察[J].山东医药,2016,54(2):80-81.
[12] Lee YJ,Kang HC,Kim HD,et al.Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy[J].Pediatr Neurol,2010,42(2):86-92.
[13] güder R,Güzel O,A

In H,et al.Efficacy and safety of IV levetiracetam in children with acute repetitive seizures[J].Pediatric Neurology,2014,51(5):688-695.
[14] Gujjar AR,Nandhagopal R,Jacob PC,et al.Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures:A prospective,randomized study[J].Seizure,2017,49:8-12.
[15] Tekgül H,Gencpinar P,avuo

lu D,et al.The efficacy,tolerability and safety of levetiracetam therapy in a pediatric population[J].Seizure,2016,36:16-21.
[16] Grosso S,Franzoni E,Coppola G,et al.Efficacy and safety of levetiracetam:an add-on trial in children with refractory epilepsy[J].Seizure,2005,14(4):248-253.
[17] Xiao F,An D,Deng H,et al.Evaluation of levetiracetam and valproic acid as low-dose monotherapies for children with typical benign childhood epilepsy with centrotemporal spikes (BECTS)[J].Seizure,2014,23(9):756-761.

左乙拉西坦治疗2岁以下婴幼儿癫痫有效性及安全性研究

Study on the effectiveness and safety of Levetiracetam in the treatment of epilepsy in infants under 2 years old

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	吴珊红, 王艳, 袁一鸣, 赵明月, 宫子涵, 张紫微, 李天益, 裴飞. 母亲产后抑郁对婴幼儿生长发育的影响[J]. 中国儿童保健杂志, 2024, 32(9): 994-998.
[2]	周琼, 刘海波, 胡必梅, 郭玉清. 母亲喂养方式、婴幼儿饮食行为及气质对儿童超重肥胖的影响[J]. 中国儿童保健杂志, 2024, 32(8): 850-855.
[3]	潘虹地, 张悦, 杨玉凤, 郑毅, 金星明, 贾美香, 静进, 邵洁, 王惠珊. 中国婴幼儿心理行为发育里程碑检查表的编制[J]. 中国儿童保健杂志, 2024, 32(7): 739-745.
[4]	孟森玲, 丁媛. 南昌市717名0~35月龄婴幼儿睡眠现状分析[J]. 中国儿童保健杂志, 2024, 32(7): 795-798.
[5]	李雪峰, 刘亚昆, 郎静, 魏守刚. 基于随机森林算法探讨血液中营养与代谢相关指标在1~6岁儿童肥胖中的相对重要性[J]. 中国儿童保健杂志, 2024, 32(6): 625-630.
[6]	孙泽容, 钱永东. 婴幼儿早期动作发育异常预测性应用进展[J]. 中国儿童保健杂志, 2024, 32(5): 538-542.
[7]	汪之顼. 婴幼儿辅食添加的新理念[J]. 中国儿童保健杂志, 2024, 32(4): 362-367.
[8]	郑岩, 司在霞, 赵丽萍, 张金. 先天性心脏病婴幼儿母乳喂养研究进展[J]. 中国儿童保健杂志, 2024, 32(4): 429-432.
[9]	冯爽, 王朝晖, 王栋, 任姣姣, 李红娟, 葛沙莎. 西安市3岁以下婴幼儿足部发育水平研究[J]. 中国儿童保健杂志, 2024, 32(4): 440-444.
[10]	马晓兰, 王慧玲, 曹婷, 马晓蓉, 徐娟娟, 韩琦, 马昊兰, 何晓阳, 马剑华, 张格祥. 临夏回族自治州6~24月龄婴幼儿贫血现状及与喂养方式的关联[J]. 中国儿童保健杂志, 2024, 32(3): 273-279.
[11]	童梅玲. 婴幼儿养育照护中早期学习机会的创设[J]. 中国儿童保健杂志, 2024, 32(2): 117-121.
[12]	董文红, 姚新萌, 许鑫, 吕丽娜, 汪沙沙, 郑双双, 王蕾, 朱冰泉, 邵洁. 婴幼儿入托影响因素及在托婴幼儿托育情况分析[J]. 中国儿童保健杂志, 2024, 32(2): 122-126.
[13]	徐玉英, 张玺, 安子芬, 余立平. 婴幼儿父母元情绪理念与家庭养育环境的相关性[J]. 中国儿童保健杂志, 2024, 32(2): 127-132.
[14]	刘潘婷, 张蕾, 洪琴, 池霞, 童梅玲, 钱君. 婴幼儿回应性照护水平和育儿信心的关系[J]. 中国儿童保健杂志, 2024, 32(2): 133-137.
[15]	公超, 连贝贝, 李雪梅, 张朋, 宋凡旭, 郭津. 脑性瘫痪共病癫痫的遗传因素、危险因素及发病机制[J]. 中国儿童保健杂志, 2024, 32(2): 174-180.